Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 5, 2004, Pages 499-504

  Lapperre, Thérèse S ^a   Snoeck Stroband, Jiska B ^b   Gosman, Margot M E ^b   Stolk, Jan ^b   Sont, Jaap K ^b   Jansen, Désirée F ^b   Kerstjens, Huib A M ^b   Postma, Dirkje S ^b   Sterk, Peter J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Bronchial hyperreactivity; Bronchodilator reversibility; Factor analysis; Induced sputum; Nitric oxide

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN E; METHACHOLINE; NITRIC OXIDE;

ADULT; AGED; AIRFLOW; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DYSPNEA; EOSINOPHIL; EXPIRED AIR; FACTORIAL ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOCYTE COUNT; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESIDUAL VOLUME; RESPIRATORY TRACT INFLAMMATION; TOTAL LUNG CAPACITY;

AGED; BREATH TESTS; CROSS-SECTIONAL STUDIES; EOSINOPHILS; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; IMMUNOGLOBULIN E; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SPUTUM;

EID: 4444272836     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200401-112OC     Document Type: Article

References (46)

1. Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003;22:1-2; www. goldcopd.com.
2. Wedzicha JA. The heterogeneity of chronic obstructive pulmonary disease. Thorax 2000;55:631-632.
3. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121(Suppl 5):121S-126S.
4. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS. The European Respiratory Society Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-1420.
5. Croxton TL, Weinmann GG, Senior RM, Hoidal JR. Future research directions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:838-844.
6. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-280.
7. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-1309.
8. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-534.
9. Peleman RA, Rytila PH, Kips JC, Joos GF, Pauwels RA. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999;13:839-843.
10. Balzano G, Stefanelli F, Iorio C, De Felice A, Melillo EM, Martucci M, Melillo G. Eosinophilic inflammation in stable chronic obstructive pulmonary disease: relationship with neutrophils and airway function. Am J Respir Crit Care Med 1999;160:1486-1492.
11. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van der Mark TW, Koeter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-18.
12. Maestrelli P, Richeldi L, Moretti M, Fabbri LM. Analysis of sputum in COPD. Thorax 2001;56:420-422.
13. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999;103:232-237.
14. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004;23:287-291.
15. Ottanelli R, Rosi E, Romagnoli I, Grazzini M, Stendardi L, Duranti R, Scano G. Do inhaled corticosteroids affect perception of dyspnea during bronchoconstriction in asthma? Chest 2001;120:770-777.
16. Gronke L, Kanniess F, Holz O, Jorres RA, Magnussen H. The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clin Exp Allergy 2002;32:57-63.
17. Ries AL, Kaplan RM, Blumberg E. Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. J Clin Epidemiol 1991;44:497-503.
18. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1185-1189.
19. van Stel HF, Bogaard JM, Rijssenbeek-Nouwens LH, Colland VT. Multivariable assessment of the 6-min walking test in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1567-1571.
20. Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;145:467-470.
21. Wegner RE, Jorres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994;7:725-729.
22. Taube C, Lehnigk B, Paasch K, Kirsten DK, Jorres RA, Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:216-220.
23. Nguyen HQ, Altinger J, Carrieri-Kohlman V, Gormley JM, Stulbarg MS. Factor analysis of laboratory and clinical measurements of dyspnea in patients with chronic obstructive pulmonary disease. J Pain Symptom Manage 2003;25:118-127.
24. Lapperre TS, Stroband JB, van Maaren MS, van der Veen H, Sont JK, Postma DS, Rabe KF, Sterk PJ. The GLUCOLD Study Group. Pathophysiological pathways in COPD: a factor analysis of lung function, airway hyperresponsiveness (AHR) and sputum cell counts. Am J Respir Crit Care Med 2002;165:A584.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Eur Respir J 1993;6:5-40.
26. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995;152:1107-1136.
27. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN, Sluiter HJ. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Interpretation of bronchodilator response in patients with obstructive airways disease. Thorax 1992;47:429-436.
28. Cotes JE, Chinn DJ, Quanjer PH, Rutgers SR, Yernault J-C. Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J 1993;6:41-52.
29. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, Juniper EF, Malo J-L. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993;6:53-83.
30. in't Veen JCCM, de Gouw HW, Smits HH, Sont JK, Hiemstra PS, Sterk PJ, Bel EH. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J 1996;9:2441-2447.
31. American Thoracic Society. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. Am J Respir Crit Care Med 1999;160:2104-2117.
32. Stevens J. Exploratory and confirmatory factor analysis. In: Stevens J, editor. Mahwah, NJ: Lawrence Erlbaum Associates; 1996. p. 362-428.
33. Global Initiative for Chronic Obstructive Lung Disease. Diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. National Heart, Lung, and Blood Institute, April 2001. Available online at: www.goldcopd.com.
34. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, Ciaccia A, Fabbri LM. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1773-1777.
35. Sitkauskiene B, Sakalauskas R, Malakauskas K, Lotvall J. Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation. Respir Med 2003;97:591-598.
36. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-664.
37. Turato G, Zuin R, Miniati M, Baraldo S, Rea F, Beghe B, Monti S, Formichi B, Boschetto P, Harari S, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologie emphysema. Am J Respir Crit Care Med 2002;166:105-110.
38. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-688.
39. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997;155:449-453.
40. Liu H, Lazarus SC, Caughey GH, Fahy JV. Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro. Am J Physiol 1999;276:L28-L34.
41. Tracey M, Villar A, Dow L, Coggon D, Lampe FC, Holgate ST. The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1: a longitudinal study in the elderly. Am J Respir Crit Care Med 1995;151:656-662.
42. Postma DS, Kerstjens HAM. Epidemiology and natural history of chronic obstructive pulmonary disease. In: Gibson GJ, Geddes DM, Costabel U, Sterk PJ, Corrin B, editors. Respiratory Medicine. London: Saunders; 2003. p. 1109-1120.
43. Kanner RE. Early intervention in chronic obstructive pulmonary disease: a review of the Lung Health Study results. Med Clin North Am 1996;80:523-547.
44. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. The Lung Health Study Research Group. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:1802-1811.
45. Yan K, Salome CM, Woolcock AJ. Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;132:25-29.
46. Sherrill DL, Halonen M, Burrows B. Relationships between total serum IgE, atopy, and smoking: a twenty-year follow-up analysis. J Allergy Clin Immunol 1994;94:954-962.